Erratum: Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (Journal of Clinical Oncology (2017) 35 (3484-3515) DOI:10.1200/JCO.2017.74.6065);Systemic therapy for stage IV non–small-cell lung cancer: American Society of clinical oncology clinical practice guideline update

Journal of Clinical Oncology

Volumn 35, Issue 30, 2017, Pages 3484-3515

  Hanna, Nasser ^a   Johnson, David ^b   Temin, Sarah ^c   Baker, Sherman ^d   Brahmer, Julie ^f   Ellis, Peter M ^g   Giaccone, Giuseppe ⁱ   Hesketh, Paul J ^j   Jaiyesimi, Ishmael ^k   Leighl, Natasha B ^h   Riely, Gregory J ^m   Schiller, Joan H ^e   Schneider, Bryan J ^l   Smith, Thomas J ^f   Tashbar, Joan ⁿ   Biermann, William A ^o   Masters, Gregory ^p  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e Inova Dwight and Martha Schar Cancer Institute   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g Juravinski Cancer Centre   (New Zealand)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^k WILLIAM BEAUMONT HOSPITAL   (United States)

^l UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ Circle of Hope for Cancer Research ^*  (United States)

^o Einstein Medical Center Montgomery   (United States)

^p HELEN F GRAHAM CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; GEMCITABINE; NIVOLUMAB; OSIMERTINIB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DYSPNEA; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; FEVER; GENE REARRANGEMENT; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; PUSTULOSIS PALMOPLANTARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEPSIS; STOMATITIS; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; THROMBOCYTOPENIA; VOMITING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EVIDENCE BASED MEDICINE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PATHOLOGY; PROCEDURES; UNITED STATES;

AMERICAN MEDICAL ASSOCIATION; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EVIDENCE-BASED MEDICINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 85032427297     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.77.2558     Document Type: Erratum

References (46)

1. Masters GA, Temin S, Azzoli CG, et al: Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3488-3515, 2015
2. Michot JM, Bigenwald C, Champiat S, et al: Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 54:139-148, 2016
3. Leighl NB, Rekhtman N, Biermann WA, et al: Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/ International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline. J Clin Oncol 32:3673-3679, 2014
4. Reck M, Rodríguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med 375:1823-1833, 2016
5. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
6. Socinski M, Creelan B, Horn L: CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1) positive NSCLC. Ann Oncol 27, 2016 (suppl 6; abstr LBA7_PR)
7. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015
8. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373: 123-135, 2015
9. Paz-Ares L, Mezger J, Ciuleanu TE, et al: Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non–squamous non-small-cell lung cancer (INSPIRE): An open-label, randomised, controlled phase 3 study. Lancet Oncol 16:328-337, 2015
10. Thatcher N, Hirsch FR, Luft AV, et al: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non–small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763-774, 2015
11. Soria JC, Felip E, Cobo M, et al: Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase 3 trial. Lancet Oncol 16:897-907, 2015
12. Rittmeyer A, Barlesi F, Watercamp D: Atezolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255-265, 2017
13. Mok TS, Wu YL, Ahn MJ, et al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629-640, 2017
14. Lynch TJ, Bondarenko I, Luft A, et al: Ipili-mumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:2046-2054, 2012
15. Langer CJ, Gadgeel SM, Borghaei H, et al: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non–small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17: 1497-1508, 2016
16. Blumenschein GR Jr, Smit EF, Planchard D, et al: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non–small-cell lung cancer (NSCLC). Ann Oncol 26:894-901, 2015
17. Vansteenkiste J, Fehrenbacher L, Spira AI, et al: Atezolizumab monotherapy vs docetaxel in 2L/ 3L non–small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Eur J Cancer 51:S716-S717, 2015 (suppl 3; abstr 14LBA)
18. Ou SH, Ahn JS, De Petris L, et al: Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: A phase II global study. J Clin Oncol 34:661-668, 2016
19. Planchard D, Besse B, Groen HJ, et al: Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non–small cell lung cancer: An open-label, multicentre phase 2 trial. Lancet Oncol 17:984-993, 2016
20. Planchard D, Kim TM, Mazieres J, et al: Dabrafenib in patients with BRAF(V600E)-positive advanced non–small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17:642-650, 2016
21. Goto K, Chih-Hsin Yang J, Kim DW: Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non–small cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl; abstr 9022)
22. Goss G, Tsai CM, Shepherd FA, et al: Osimertinib for pretreated EGFR Thr790Met-positive advanced non–small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17:1643-1652, 2016
23. Jänne PA, Yang JC, Kim DW, et al: AZD9291 in EGFR inhibitor-resistant non–small-cell lung cancer. N Engl J Med 372:1689-1699, 2015
24. Ellis PM, Vella ET, Ung YC: Systemic treatment for patients with advanced non-small cell lung cancer. Toronto (ON): Cancer Care Ontario; 2016 November 14. Program in Evidence-Based Care Guideline No.: 7-10, Version 3
25. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19:94-101, 2012
26. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 147:224-233, 2007
27. Gralla RJ, Coon C, Taylor F, et al: Evaluation of disease-related symptoms in patients (pts) with advanced squamous (SQ) non–small cell lung cancer (NSCLC) treated with nivolumab (NIVO) or docetaxel (DOC). Oncol Res Treat 38:14-16, 2015
28. Reck M, Coon C, Taylor F, et al: Evaluation of overall health status in patients with advanced squamous non–small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017. Eur J Cancer 51:S599-S600, 2015
29. Engel-Riedel W, Schneller F, Wolf M, et al: Imprime PGG, a novel immune modulator, in the 1st-line treatment of stage IV NSCLC: Results from a randomized, controlled, multicenter phase 2 study. Ann Oncol 25, 2014 (abstr LBA32)
30. US Food and Drug Administration: Pembrolizumab (Keytruda) 5-10-2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm558048.htm
31. US Food and Drug Administration: Highlights of prescribing information. KEYTRUDA (pembrolizumab) for injection, for intravenous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf
32. US Food and Drug Administration: Highlights of prescribing information: PORTRAZZA (necitumumab).https://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/125547s000lbl.pdf
33. Ellis LM, Bernstein DS, Voest EE, et al: American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32:1277-1280, 2014
34. Gettinger SN, Bazhenova LA, Langer CJ, et al: Activity and safety of brigatinib in ALK-rearranged non–small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1/2 trial. Lancet Oncol 17:1683-1696, 2016
35. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
36. US Food and Drug Administration: Highlights of prescribing information: TARCEVA (erlotinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
37. Lee CK, Man J, Lord S, et al: Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer: A meta-analysis. J Thorac Oncol 12: 403-407, 2017
38. Saito AM, Landrum MB, Neville BA, et al: The effect on survival of continuing chemotherapy to near death. BMC Palliat Care 10:14, 2011
39. Saito AM, Landrum MB, Neville BA, et al: Hospice care and survival among elderly patients with lung cancer. J Palliat Med 14:929-939, 2011
40. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. http://seer.cancer.gov/csr/ 1975_2013/
41. American Cancer Society: Cancer Facts & Figures for African Americans 2016-2018. Atlanta, GA, American Cancer Society, 2016. http://www.cancer.org/acs/groups/content/ editorial/documents/ document/acspc-047403.pdf
42. US Cancer Statistics Working Group: United States Cancer Statistics: 1999–2012 Incidence and Mortality Web-Based Report. Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2015
43. Mead H, Cartwright-Smith L, Jones K, et al. Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. Commonwealth Fund, New York, NY. 2008.
44. Ferrell BR, Temel JS, Temin S, et al: Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:96-112, 2017
45. Paice JA, Portenoy R, Lacchetti C, et al: Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:3325-3345, 2016
46. Hesketh P, Kris M, Basch E, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240-3261, 2017